Your browser doesn't support javascript.
loading
Some current issues relating to rubella vaccine.
JAMA ; 254(2): 253-6, 1985 Jul 12.
Article em En | MEDLINE | ID: mdl-3999370
ABSTRACT
At the time of licensure in 1969, available data indicated that rubella vaccines were safe, noncommunicable, and effective. Since vaccine virus could cross the placenta and infect the fetus, cautious use of the vaccines in childbearing-age women was recommended. Over the past 15 years, additional information about the vaccines has been accumulated. This article provides an update of data on (1) the risk and degree of joint symptoms following vaccination and revaccination, (2) the duration of vaccine-induced immunity, (3) the protective effect of low levels of vaccine-induced antibody, and (4) the risks to the fetus following maternal vaccination. The data support continued vaccination of all young children as well as increased efforts to vaccinate susceptible adolescents and young adults, especially women. Only by more effective vaccination of the latter can elimination of congenital rubella syndrome be hastened.
Assuntos
Buscar no Google
Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacina contra Rubéola Tipo de estudo: Etiology_studies / Risk_factors_studies Limite: Adult / Child / Female / Humans / Male / Newborn / Pregnancy Idioma: En Ano de publicação: 1985 Tipo de documento: Article
Buscar no Google
Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacina contra Rubéola Tipo de estudo: Etiology_studies / Risk_factors_studies Limite: Adult / Child / Female / Humans / Male / Newborn / Pregnancy Idioma: En Ano de publicação: 1985 Tipo de documento: Article